SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "LAR1:gu ;pers:(Ohlsson Claes 1965)"

Sökning: LAR1:gu > Ohlsson Claes 1965

  • Resultat 1-10 av 263
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Almehed, Katarina, 1966-, et al. (författare)
  • Prevalence and risk factors of osteoporosis in female SLE patients-extended report
  • 2007
  • Ingår i: Rheumatology (Oxford). - 1462-0324 (Print). ; 46:7, s. 1185-90
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVES: To determine the frequency of osteoporosis and possible risk factors of low bone mineral density (BMD) in women with systemic lupus erythematous (SLE) in western Sweden. In addition, to evaluate if adequate anti-osteoporotic treatment was provided. METHODS: BMD was measured at radius, lumbar spine and hip by dual X-ray absorptiometry (DXA). An 'expected' control BMD was calculated for each patient. Simple and multiple linear regression analyses were performed to determine associations between BMD and demographic and disease-related variables. RESULTS: One hundred and sixty-three women were included. Median age was 47 (20-82) yrs, 89 (55%) were post-menopausal and 85 (52%) were taking glucocorticosteroids. BMD was significantly reduced in all measured sites compared with expected BMD. Thirty-seven (23%), 18 (11%) and 6 (4%) of the patients were osteoporotic in at least one, two and three or more measured locations. Bisphosphonates were used by 23 (27%) of patients taking glucocorticosteroids and 13 (35%) with osteoporosis. High age and low weight or BMI were associated with low BMD in all measured sites. In total hip, high SLICC/American Collage of Rheumatology (ACR), ESR and 'combinations of DMARD' were additional markers of low BMD. High S-creatinine was associated with low BMD in lumbal spine whereas high S-creatinine and CRP were markers in radius. CONCLUSION: Women with SLE are at greater risk of osteoporosis compared with controls and few are treated adequately. Factors associated with low BMD in SLE are high age and low weight but also markers of inflammation, impaired kidney function and disease damage, however glucocorticosteroids were not associated.
  •  
2.
  •  
3.
  • Andersson, Annica, 1983-, et al. (författare)
  • Suppression of Experimental Arthritis and Associated Bone Loss by a Tissue-Selective Estrogen Complex.
  • 2016
  • Ingår i: Endocrinology. - 1945-7170. ; 157:3, s. 1013-20
  • Tidskriftsartikel (refereegranskat)abstract
    • In addition to the systemic inflammation present in rheumatoid arthritis (RA), decreased estradiol levels in postmenopausal RA patients further accelerate bone loss in these patients. The tissue-selective estrogen complex (TSEC), an estrogen combined with a selective estrogen receptor modulator, is a new hormone replacement therapy option. The first approved TSEC, containing conjugated estrogens and bazedoxifene (BZA), reduces menopausal symptoms and prevents osteoporosis with an improved safety profile compared with conventional hormone replacement therapy. Previous studies have shown that estrogens strongly inhibit experimental arthritis whereas BZA is mildly suppressive. In this study the antiarthritic potential of combined BZA and estradiol is explored for the first time. Female ovariectomized DBA/1 mice were subjected to collagen-induced arthritis, an experimental postmenopausal RA model, and treated with BZA, 17β-estradiol (E2), combined BZA and E2 (BZA/E2), or vehicle. BZA/E2 suppressed arthritis severity and frequency, synovitis, and joint destruction, equally efficient as E2 alone. Unwanted estrogenic proliferative effects on the endometrium were blocked by the addition of BZA, determined by collecting uterine weights. Bone mineral density was measured by peripheral quantitative computed tomography, and all treatments protected collagen-induced arthritis mice from both trabecular and cortical bone loss. Moreover, BZA/E2, but not E2 alone, inhibited preosteoclast formation and reduced serum anticollagen type II antibodies. In conclusion, a TSEC, herein combined BZA/E2, suppresses experimental arthritis and prevents associated bone loss as efficiently as E2 alone but with minimal uterine effects, highlighting the need for clinical trials that evaluate the addition of a TSEC to conventional postmenopausal RA treatment.
  •  
4.
  • Andersson, Niklas, 1970-, et al. (författare)
  • Investigation of central versus peripheral effects of estradiol in ovariectomized mice
  • 2005
  • Ingår i: J Endocrinol. - 0022-0795 (Print). ; 187:2, s. 303-9
  • Tidskriftsartikel (refereegranskat)abstract
    • It is generally believed that estrogens exert their bone sparing effects directly on the cells within the bone compartment. The aim of the present study was to investigate if central mechanisms might be involved in the bone sparing effect of estrogens. The dose-response of central (i.c.v) 17beta-estradiol (E2) administration was compared with that of peripheral (s.c.) administration in ovariectomized (ovx) mice. The dose-response curves for central and peripheral E2 administration did not differ for any of the studied estrogen-responsive tissues, indicating that these effects were mainly peripheral. In addition, ovx mice were treated with E2 and/or the peripheral estrogen receptor antagonist ICI 182,780. ICI 182,780 attenuated most of the estrogenic response regarding uterus weight, retroperitoneal fat weight, cortical BMC and trabecular bone mineral content (P<0.05). These findings support the notion that the primary target tissue that mediates the effect of E2 on bone is peripheral and not central.
  •  
5.
  • Andersson, Niklas, 1970-, et al. (författare)
  • Repeated in vivo determinations of bone mineral density during parathyroid hormone treatment in ovariectomized mice.
  • 2001
  • Ingår i: The Journal of endocrinology. - 0022-0795. ; 170:3, s. 529-37
  • Tidskriftsartikel (refereegranskat)abstract
    • The recent development of different genetically modified mice with potentially interesting bone phenotypes has increased the demand for effective non-invasive methods to evaluate effects on bone of mice during growth and development, and for drug evaluation. In the present study, the skeleton was analyzed by repeated in vivo scans using dual energy X-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT). Ovariectomized (ovx) mice treated with parathyroid hormone (PTH) were used as an animal model to evaluate these two techniques at different times after the onset of treatment. Female mice (6 weeks of age) were allocated randomly to four groups: (1) sham-operated+vehicle; (2) ovx+vehicle; (3) sham-operated+PTH(1-84) 150 microg/kg per day; (4) ovx+PTH. Six weeks after ovariectomy the drug treatment began and was continued for 8 weeks. The total body bone mineral content (BMC) and total body areal bone mineral density (BMD) were measured by DXA. Ovariectomy reduced total body BMC and total body areal BMD by 6.2+/-1.7% and 2.6+/-0.9% respectively. No effect of PTH on total body BMC was seen during the treatment period. The trabecular volumetric BMD was measured by pQCT. Ovariectomy reduced the trabecular volumetric BMD by 52+/-6.7%. The pQCT technique detected a clear effect on trabecular volumetric BMD after 2 weeks of PTH treatment (ovx 94+/-29% and sham-operated 46+/-10% more than vehicle-treated). The cortical bone was measured in a mid-diaphyseal pQCT scan of the tibia. Ovariectomy reduced the cortical BMC by 9+/-2%. PTH treatment for 8 weeks increased cortical BMC in ovx mice. In conclusion, the pQCT technique is more sensitive than the DXA technique in the detection of bone loss after ovariectomy and increased bone mass after PTH treatment in mice. Notably, the pQCT, but not the DXA, technique detected a dramatic effect as early as after 2 weeks of PTH treatment. Dynamic pQCT measurements will be useful for monitoring skeletal changes during growth and development, and for drug evaluation in mice.
  •  
6.
  • Astrand, Annika, et al. (författare)
  • Mice lacking melanin-concentrating hormone receptor 1 demonstrate increased heart rate associated with altered autonomic activity.
  • 2004
  • Ingår i: American journal of physiology. Regulatory, integrative and comparative physiology. - 0363-6119. ; 287:4, s. R749-58
  • Tidskriftsartikel (refereegranskat)abstract
    • Melanin-concentrating hormone (MCH) plays an important role in energy balance. The current studies were carried out on a new line of mice lacking the rodent MCH receptor (MCHR1(-/-) mice). These mice confirmed the previously reported lean phenotype characterized by increased energy expenditure and modestly increased caloric intake. Because MCH is expressed in the lateral hypothalamic area, which also has an important role in the regulation of the autonomic nervous system, heart rate and blood pressure were measured by a telemetric method to investigate whether the increased energy expenditure in these mice might be due to altered autonomic nervous system activity. Male MCHR1(-/-) mice demonstrated a significantly increased heart rate [24-h period: wild type 495 +/- 4 vs. MCHR1(-/-) 561 +/- 8 beats/min (P < 0.001); dark phase: wild type 506 +/- 8 vs. MCHR1(-/-) 582 +/- 9 beats/min (P < 0.001); light phase: wild type 484 +/- 13 vs. MCHR1(-/-) 539 +/- 9 beats/min (P < 0.005)] with no significant difference in mean arterial pressure [wild type 110 +/- 0.3 vs. MCHR1(-/-) 113 +/- 0.4 mmHg (P > 0.05)]. Locomotor activity and core body temperature were higher in the MCHR1(-/-) mice during the dark phase only and thus temporally dissociated from heart rate differences. On fasting, wild-type animals rapidly downregulated body temperature and heart rate. MCHR1(-/-) mice displayed a distinct delay in the onset of this downregulation. To investigate the mechanism underlying these differences, autonomic blockade experiments were carried out. Administration of the adrenergic antagonist metoprolol completely reversed the tachycardia seen in MCHR1(-/-) mice, suggesting an increased sympathetic tone.
  •  
7.
  • Auyeung, T. W., et al. (författare)
  • Sleep Duration and Disturbances Were Associated With Testosterone Level, Muscle Mass, and Muscle Strength-A Cross-Sectional Study in 1274 Older Men
  • 2015
  • Ingår i: Journal of the American Medical Directors Association. - 1525-8610. ; 16:7
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Testosterone level follows a circadian rhythm. However, whether sleep duration and disturbances can affect testosterone level, muscle mass, and strength remains unknown. Objective: To examine the relationship of sleep duration and disturbances to testosterone level, muscle mass, muscle strength, and walking speed. Participants and methods: We recruited 1274 community-dwelling men older than 65 years of age. Their early morning testosterone level was assayed by mass spectrometry. A sleep questionnaire was administered to enquire about their reported sleep duration, prolonged sleep latency (>0.5 hour), and subjective insomnia complaint. Muscle mass was measured by dual-energy x-ray absorptiometry. Testosterone level, muscle mass, handgrip strength, and walking speed were tested against sleep duration and disturbances. Results: Testosterone increased with increasing sleep duration up to 9.9 hours, after which it decreased, giving rise to an inverted U-shaped relationship (P for quadratic trend < .05). A similar inverted U-shaped relationship occurred between sleep duration and muscle mass and function. Earlier go-to-bed time, despite being associated with a higher testosterone level (P < .05), was associated with weaker grip strength (P < .05). Earlier wake-up time was associated with higher muscle mass (P < .05) but neither grip strength nor walking speed. Neither prolonged sleep latency nor insomnia was associated with testosterone levels. However, prolonged sleep latency was associated with lower muscle mass (P < .05), weaker grip strength (P < .05), and slower walking speed (P < .001). Insomnia, on the other hand was associated with weaker grip strength (P < .05) and slower walking speed (P < .001) but not muscle mass. Conclusions: Sleep duration and disturbances can affect testosterone level, muscle mass, and its function. Whether optimization of sleep can ameliorate age-associated decline in sex hormone and muscle performance warrants further studies. (C) 2015 AMDA - The Society for Post-Acute and Long-Term Care Medicine.
  •  
8.
  •  
9.
  • Benrick, Anna, 1979-, et al. (författare)
  • A non-conservative polymorphism in the IL-6 signal transducer (IL6ST)/gp130 is associated with myocardial infarction in a hypertensive population.
  • 2008
  • Ingår i: Regulatory peptides. - 0167-0115. ; 146:1-3, s. 189-96
  • Tidskriftsartikel (refereegranskat)abstract
    • Inflammation is a key component in the development of atherosclerosis, and myocardial infarction (MI); therefore we investigated the association between an interleukin-6 signal transducer (IL6ST)/gp130 polymorphism, gp130 function and risk of MI. Structural modeling suggested that a non-conservative single nucleotide polymorphism in the gp130, Gly148Arg, can change the stability and functional properties of the molecule. In vitro studies were done with BAF/3 cells lacking endogenous gp130. Cells stably transfected with the gp130 148Arg variant proliferated less and showed slightly lower STAT-3 phosphorylation in response to gp130 stimulation as compared to cells transfected with gp130 148Gly. In a prospectively followed hypertensive cohort we identified 167 patients who suffered a MI during the study and compared them to matched controls (mean age 57 years, 73% males, n=482). Carriers of the 148Arg variant (f(Arg)=0.12) of the gp130 receptor had decreased odds ratio for MI in univariate analysis (0.56, 95% CI 0.34-0.91, p=0.02). In conclusion, a genetically determined structural variant of the IL-6 receptor subunit gp130 is, independently of other known risk factors, associated with decreased risk of MI. The variant is also associated with decreased IL-6 responsiveness and could lead to a configuration change in the gp130 receptor.
  •  
10.
  • Benrick, Anna, 1979-, et al. (författare)
  • Resveratrol Is Not as Effective as Physical Exercise for Improving Reproductive and Metabolic Functions in Rats with Dihydrotestosterone-Induced Polycystic Ovary Syndrome
  • 2013
  • Ingår i: Evidence-Based Complementary and Alternative Medicine. - 1741-427X. ; Article ID 964070
  • Tidskriftsartikel (refereegranskat)abstract
    • Polycystic ovary syndrome (PCOS) is a reproductive and metabolic disorder associated with obesity and insulin resistance that often precedes the development of type-2 diabetes. Rats continuously exposed to dihydrotestosterone from prepuberty display typical reproductive and metabolic PCOS characteristics including anovulation, polycystic ovaries, insulin resistance, and obesity. Our aim was to investigate if resveratrol improves reproductive and metabolic functions in PCOS rats. The effect was compared to exercise. Control and PCOS rats were treated with vehicle or resveratrol (400 mg · kg−1 · day−1) for 5-6 weeks. Another group of PCOS rats received vehicle treatment and exercised for 5-6 weeks. Insulin sensitivity was determined by euglycemic-hyperinsulinemic clamp. The glucose infusion rate was lower in the PCOS-vehicle group compared to control-vehicle rats (). Exercise increased insulin sensitivity compared with PCOS-vehicle rats (), but resveratrol did not. Resveratrol treatment and exercise resulted in smaller adipocytes, upregulated estrogen-related receptor α gene expression in subcutaneous fat, and improved estrus cyclicity in the previously acyclic PCOS rats. Although resveratrol had positive effects on adiposity and cyclicity in a similar manner to exercise, resveratrol does not seem to be a good candidate for treating insulin resistance associated with PCOS because no improvement in insulin sensitivity was observed in PCOS rats on normal chow.
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 263
Åtkomst
fritt online (9)
Typ av publikation
tidskriftsartikel (260)
forskningsöversikt (2)
bokkapitel (1)
Typ av innehåll
refereegranskat (256)
övrigt vetenskapligt (7)
Författare/redaktör
Lorentzon, Mattias, ... (49)
Mellström, Dan, 1945 ... (47)
Sjögren, Klara, 1970 ... (35)
Vandenput, Liesbeth, ... (34)
Isaksson, Olle, 1943 ... (34)
visa fler...
Carlsten, Hans, 1954 ... (28)
Jansson, John-Olov, ... (26)
Movérare-Skrtic, Sof ... (22)
Islander, Ulrika, 19 ... (17)
Windahl, Sara H, 197 ... (17)
Nilsson, Anders, 195 ... (17)
Lagerquist, Marie, 1 ... (17)
Eriksson, Anna-Lena, ... (16)
Lindahl, Anders, 195 ... (15)
Svensson, Johan, 196 ... (15)
Börjesson, Anna E (15)
Engdahl, Cecilia, 19 ... (12)
Tivesten, Åsa, 1969- ... (12)
Stubelius, Alexandra ... (11)
Törnell, Jan, 1960-, (11)
Swolin-Eide, Diana, ... (10)
Kindblom, Jenny, 197 ... (10)
Andersson, Annica, 1 ... (9)
Lagerquist, Marie K, (9)
Andersson, Niklas, 1 ... (9)
Mohan, Subburaman (9)
Nilsson, Staffan, 19 ... (8)
Vidal, Olle, (8)
Farman, Helen H., (8)
Nilsson, Martin, 196 ... (8)
Vanderschueren, Dirk ... (7)
Swanson, Charlotte, ... (7)
Isgaard, Jörgen, 195 ... (7)
Woo, Jean (7)
Bengtsson, Bengt-Åke ... (6)
Norjavaara, Ensio, 1 ... (6)
Dickson, Suzanne L., ... (6)
Lundholm, Kent, 1945 ... (6)
Bohlooly-Yeganeh, Mo ... (6)
Kwok, Timothy (6)
Leung, Ping Chung (6)
Hedner, Thomas, 1949 ... (6)
Darelid, Anna, (6)
Jochems, Caroline, 1 ... (6)
Skrtic, Stanko, 1970 ... (6)
Wallenius, Kristina, ... (6)
Lerner, Ulf H, (5)
Grahnemo, Louise, (5)
Svanberg, Elisabeth, ... (5)
visa färre...
Lärosäte
Göteborgs universitet (263)
Chalmers tekniska högskola (12)
Karolinska Institutet (7)
Lunds universitet (2)
Uppsala universitet (1)
Språk
Engelska (255)
Svenska (5)
Odefinierat språk (3)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (263)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy